# Weight-based Dosing in Hemophilia A

> **NCT02586012** · PHASE2 · TERMINATED · sponsor: **Craig Seaman** · enrollment: 30 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **DRUG:** rFVIII

## Key facts

- **NCT ID:** NCT02586012
- **Lead sponsor:** Craig Seaman
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2020-01-10
- **Final completion:** 2020-01-10
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Insufficient enrollment
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586012, "Weight-based Dosing in Hemophilia A". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02586012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*